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Caloric restriction, physical 
exercise, and CB1 receptor 
blockade as an efficient combined 
strategy for bodyweight control 
and cardiometabolic status 
improvement in male rats
Luisa M. Lopez Trinidad1,3, Rosario Martinez1,3, Garyfallia Kapravelou1, Milagros Galisteo2, 
Pilar Aranda1, Jesus M. Porres1* & Maria Lopez‑Jurado1
Obesity is critically associated with the development of insulin resistance and related cardiovascular 
and kidney diseases. Several strategies for weight loss have been developed but most of them exhibit 
a post‑intervention rebound effect. Here, we aimed to design combined weight‑loss strategies 
of caloric restriction, physical exercise, and administration of a CB1 receptor blocker to inhibit 
food intake that also accomplish the objectives of lost‑weight maintenance and improvement of 
cardiovascular and renal function. Diet‑induced obesity (DIO) was generated in Sprague Dawley 
rats for 12 weeks to test the effects of single or combined strategies (i.e. caloric restriction, mixed 
training protocol, and/or administration of appetite suppressant) on caloric intake, body weight, 
cardiovascular and renal functionality resulting from a weight‑loss intervention period of 3 weeks 
followed by 6 weeks of weight maintenance. Consumption of a high‑fat diet (HFD) caused a significant 
increase in body weight (5th week of the experimental period) and led to the development of insulin 
resistance, cardiovascular, and renal alterations. The different interventions tested, resulted in a 
significant body weight loss and improved glucose metabolism, aerobic capacity, electrocardiographic 
parameters, vascular expression of adhesion molecules and inflammatory mediators, and renal 
functionality, reaching values similar to the control normocaloric group or even improving them. 
Successful maintenance of lost weight was achieved along a 6‑week maintenance period in addition to 
adequate health status. In conclusion, the weight‑loss and maintenance intervention strategies tested 
were efficient at reversing the obesity‑related alterations in body weight, glucose metabolism, aerobic 
capacity, cardiovascular and renal functionality. The beneficial action was very consistent for caloric 
restriction and physical exercise, whereas administration of a CB1 receptor blocker complemented 
the effects of the prior interventions in some parameters like body weight or aerobic capacity, and 
showed specific actions in renal status, increasing glomerular filtration rate and diuresis. Overall, the 
novelty of our study relies on the easy implementation of combined strategies for effective weight 
management that resulted in significant health benefits.
Overweight and obesity are defined as abnormal or excessive fat accumulation that increases the risk to develop 
multiple pathologies. They lead to adverse metabolic effects on blood pressure, cholesterol, triglycerides, and 
insulin resistance. This compilation of factors is known as metabolic syndrome (MetS)1, which is directly related 
to cardiovascular disease and the alteration in other vital functions, such as the renal  function2. Overweight, 
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obesity and its related diseases are largely  preventable3. In this regard, a comprehensive understanding of MetS 
may be important for the adequate planning of prevention strategies. Since its components are all reversible, 
early diagnosis and lifestyle intervention strategies of MetS offer an effective treatment approach, primarily 
targeting weight management.
The control and maintenance of the body weight at a stable level are achieved when there is a balance between 
food intake and energy expenditure. A complex physiological control system is involved in the maintenance of 
the energy balance and includes afferent signals from the periphery regarding the state of energy stores, as well 
as efferent signals affecting energy intake and  expenditure4. This regulatory system includes multiple interactions 
between the gastrointestinal tract, adipose tissue and central nervous system, and is influenced by behavioral, 
sensorial, autonomic, nutritional and endocrine  mechanisms5.
The first step in the treatment of obesity is focused on losing the extra-weight and ameliorate the related 
metabolic alterations. Another important issue for subjects who complete a weight loss program is to avoid the 
post-intervention rebound effect. The bodyweight regain usually takes place right after the end of weight loss 
intervention as weight loss programs are just  transient6. A multidisciplinary approach is required, including 
lifestyle  modifications7 and, in some cases, the reinforcement with pharmacological treatment. Related to lifestyle 
interventions there are two core aspects to correct an altered energy balance: diet and physical exercise. Obesity 
development is often favored by the consumption of unbalanced and hypercaloric diets, so the caloric restric-
tion of a balanced diet providing adequate amounts of nutrients is highly recommended. On the other hand, 
physical activity plays an essential role in the prevention and treatment of obesity. It contributes to generating 
a negative energy balance, thus facilitating weight loss and avoiding the rebound effect and subsequent body 
weight  regain8. It is well established that different training protocols induce changes in a variety of molecular 
mechanisms involved in numerous intracellular pathways related to glucose and lipid metabolism, inflamma-
tion, or antioxidant  status9.
In addition to lifestyle modifications, the prescription of an appropriate pharmacological agent is sometimes 
recommended. The endocannabinoid system is comprised by cannabinoid receptors 1 and 2 (CB1 and CB2), the 
two endocannabinoids anandamide and 2-arachidonoylglycerol, and endocannabinoid anabolic and catabolic 
 enzymes10. The endocannabinoid system (ECS) plays a critical role in obesity development in both central and 
peripheral functions related to energy  metabolism11. At the central level, endocannabinoids act as retrograde 
neuromodulators of synaptic plasticity, and participate in many physiological processes including pain regulation, 
learning and memory, appetite and food intake, lipogenesis, and  cravings12,13. At the peripheral level, endocan-
nabinoids exert a tonic action on lipogenesis and fat accumulation. Therefore, CB1 blockade may result in a food 
intake-independent decrease in fat mass through  lipolysis14. In fact, CB1 blockade has been shown to be effec-
tive in ameliorating obesity and related metabolic  disorders15. In addition, the endocannabinoid 2-AG prevent 
myotube formation in a manner antagonized by CB1 knockdown and by CB1 antagonists, which per se, instead, 
stimulate  differentiation16. Moreover, antagonism of CB1 receptor reduced human satellite cell proliferation and 
enhanced the formation of myotubes representing an adjuvant therapy of muscle  dystrophies17.
In recent years, the discovery of an expanded endocannabinoid system, the endocannabinoidome, which 
includes several mediators that are biochemically related to the endocannabinoids, and their receptors and 
metabolic enzymes, has corroborated its complexity and expanded the potential for developing new therapeutic 
strategies to treat multiple related pathologies including neurological, inflammatory or metabolic  alterations10.
Given the above mentioned, we hypothesized that our specific combined strategy of lifestyle and pharmaco-
logical interventions could provide interesting benefits in the treatment of obesity and its related cardiovascular 
and renal alterations. Therefore, this study aimed to design these new strategies and test them in an experimental 
model of DIO. Specifically, we sought to (1) test the effects on body weight, physical performance, glycaemic 
and lipid profile, and different parameters related to cardiovascular and renal health, of a combined program 
with caloric restriction, mixed training exercise protocol, and pharmacological treatment with the appetite sup-
pressant AM251, a well-known research tool that effectively blocks CB1 receptors and exhibits a strong food 
intake inhibition action combined with increased basal metabolic rate and decreased plasma levels of glucose 
and LDL-cholesterol. (2) study the synergies taking place between the three above-mentioned strategies both on 
body weight loss and in the maintenance of weight and metabolic, cardiovascular and renal benefits acquired.
Figure 1.  Effects of DIO and weight control interventions on caloric intake, body weight, body weight/
femur length ratio, and hypothalamic gene expression of transcripts involved in the central regulation of food 
intake and energy balance. Six control experiments were carried out during 21 weeks using a standard rat 
chow diet (SD12, SD15, and SD21) or a high-fat diet to induce obesity (HFD12, HFD15, and HFD21). For 
intervention trials, rats were divided into 8 groups that were fed the hypercaloric diet to induce obesity for 
12 weeks, followed by three weeks of intervention with a high protein diet for weight loss (WL15) combined 
or not with the training protocol (e or s, respectively) and the pharmacological treatment with CB1 receptor 
blocker AM251 (AM). The intervention period was followed by an additional 6-week weight-maintenance 
period of dietary treatment with a standard rat chow diet (WM21) combined or not with the training protocol 
(e or s, respectively) and the pharmacological treatment (AM) to maintain the weight lost during the previous 
intervention period of three weeks. (A) Experimental design, (B) average daily caloric intake (kcal/day) along 
the different experimental stages (DIO, weight-loss intervention, and weight-maintenance), (C) average body 
weight at the end of the different experimental stages, (D) bodyweight/ femur length ratio (g/cm2) at the end of 
the different experimental stages, (E) hypothalamic gene expression at the end of the weight-loss intervention 
and weight-maintenance stages. Results are means of eight rats ± SEM depicted by vertical bars. ***P < 0.001 in 
t-test (12 weeks); A,B,C means with different letters are significantly different (ANOVA treatment, P < 0.05; 15 
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Results
Combined weight control strategies efficiently achieve weight loss and prevent body weight 
rebound after treatment. The effects of DIO and different weight-loss and weight-maintenance interven-
tions on daily caloric intake and body weight at the end of the different experimental stages are presented in 
Fig. 1A–C.
Throughout the experimental period, and due to the higher caloric content of HFD, a significantly higher 
caloric intake was exhibited by HFD-treated rats when compared to their normocaloric controls. Likewise, higher 
body weight was gained by the former animals. During the weight-loss intervention period from week 12–15 of 
the experimental period, the individual action of caloric restriction, physical exercise, and AM251 administration 
caused a decrease in caloric intake that led to a concomitant decrease in body weight of treated rats. However, 
stronger effects were observed when the three interventions were combined. Along the weight-maintenance 
stage, a stabilization of caloric intake and maintenance of bodyweight among the different intervention groups 
were achieved below the values shown by the SD and HFD controls. Besides, the training protocol and the 
administration of the appetite suppressant played a role to avoid the rebound effect on body weight. These ben-
eficial actions on body weight were reflected on a similar trend in body weight/femur length ratio at the different 
experimental stages, especially when exercise was combined with AM251 administration. (Fig. 1C). Such ratio 
has been considered representative of the body mass index and adequate to establish the degree of obesity and 
evolution of rats in a long experimental period.
The expression of c-fos and Npy increased in animals fed the HFD on weeks 15 and 21 compared to the SD 
group, and decreased as a result of bodyweight loss. Such decrease was only observable in Npy during the lost-
weight maintenance stage (Fig. 1D). The administration of AM251 showed an inhibitory action on Npy and 
CB1 receptor.
Weight‑loss interventions cause a significant improvement in aerobic capacity and glycemic 
profile. Overall, DIO caused a significant decrease in aerobic capacity and physical fitness parameters (dis-
tance and maximum speed) compared to the SD group at the end of week 21 of experimental period (Fig. 2A). 
The interventions assayed for bodyweight control were efficient at increasing the above-mentioned parameters 
vs the HFD groups and the combined effects of caloric restriction and physical exercise (WMe) were of especial 
relevance. Moreover, such effects were potentiated by AM251 administration that resulted in the highest values 
for all three parameters in the WMeAM group (P < 0.05). Glycemic profile and AUC after an oral glucose over-
load carried out at the end of every experimental stage are shown in Fig. 2B,C. DIO resulted in higher AUC, a 
higher postprandial blood glucose peak after 30 min of administration, and higher values of glycemia during a 
more prolonged period after glucose overload, when compared to the SD group. These data point to a situation 
of insulin resistance, which was reversed by the weight-loss/maintenance interventions assayed.
Cardiovascular functionality is significantly improved by weight‑loss and remains stable dur‑
ing the maintenance period. The obesity-related increase in body weight led to a hypertrophied heart 
whereas weight-loss interventions decreased heart weight to similar values as those found in the SD group in 
all experimental stages (Table 1). Similarly, ventricular electrocardiographic parameters were strongly affected 
in the HFD groups that showed a significant increase in the amplitudes of QRS complex and T wave along the 
experimental period. The increased amplitudes were reversed upon body weight loss achieved by the different 
interventions assayed, reaching values that were equal or even inferior to the SD group. About the QTc interval, 
it was increased by obesity and tended to decrease by caloric restriction and physical exercise except for group 
WMeAM on week 21. No relevant changes were observed in any of the parameters related to atrial functionality. 
Plasma activity of CK-MB was increased in animals that consumed the HFD on weeks 15 and 21 and decreased 
by the different weight-loss interventions in these experimental stages (Table 2).
Gene expression of transcripts related to vascular adhesion and angiogenesis (Vcam, Sele, Vegfa) were higher 
in the aorta of HFD vs SD controls after 21 weeks of the experimental period (Fig. 3A). In contrast, the different 
weight-loss and maintenance interventions caused a significant decrease in expression levels to values lower 
than those observed in SD. Such changes were matched by significant improvements in plasma atherogenic 
index (Fig. 3B). Likewise, gene expression of Nos2, related to the inflammatory status, was higher in the aorta 
of HFD-fed animals and this increment was reversed by weight control interventions that also down-regulated 
Ptgs2 expression.
Obesity‑induced alterations in renal function and antioxidant capacity are reverted by the 
weight‑loss and maintenance strategies implemented. Creatinine clearance ratio was significantly 
increased under our experimental conditions by DIO and AM251 administration during the first 2 stages of the 
experimental period (Table 3). Also, the obesity-related increase was associated with incipient albuminuria at 
15 weeks that became significant at 21 weeks (HFD vs SD). Such was not the case with AM251 administration 
in which no albuminuria was detected. Creatinine clearance ratio also appeared to be affected by age of the 
animals and increased in SD rats at 21 vs 12 or 15 weeks. In contrast, caloric restriction and physical exercise 
tended to normalize all the above markers of altered renal functionality although results did not reach statistical 
significance in all cases.
Regarding the urinary volume and parameters related to kidney stone formation, obesity induction led to a 
considerable decrease in urinary volume and pH as well as increased phosphaturia at weeks 12 and 15, which 
run in parallel to a decreased calciuria and increased calcemia (Table 2). The metabolic status of both minerals 
tended to be normalized by the weight control strategies implemented. Renal functionality was also affected by 
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age of the animals, and considerable changes in urinary pH, phosphaturia, calciuria, and renal clearance were 
evident in the rats fed the SD diet on week 21 compared to weeks 12 and 15.
To assess whether obesity-induced changes in renal functionality could be mediated through increased oxida-
tive stress, the kidney activity of antioxidant enzymes and lipid peroxidation were assessed (Table 4). Results are 
complex and numerous interactions are observable among obesity and weight-loss interventions on the former 
parameters. Consumption of HFD worsened oxidative stress conditions and resulted in higher Mn-SOD and GPX 
activities in all the stages of the experimental period, whereas Cu/Zn-SOD activity exhibited an HFD-derived 
increase on week 15 and a reduction on week 21. The effects of weight control interventions differed based on 
their implementation during the 3 weeks of weight-loss or the 6 weeks of weight-maintenance.
Specifically, on week 21 of experimental period, there was a significant decrease in Mn-SOD activity caused 
by the combined action of exercise and AM251 administration. Likewise, a marked decrease was also found in 
GPX activity caused by the administration of AM251, alone or in combination with physical exercise.
Discussion
The present study was carried out to assess the changes produced by obesity on some cardio-renal functions and 
to demonstrate the improvement in these functions due to a decrease in bodyweight and maintenance of lost 
weight. Caloric restriction, physical exercise, and blockade of CB1 receptor strategies were tested in an animal 
model of DIO.
Under our experimental conditions, obesity was successfully established (difference in body weight between 
normocaloric and HFD-fed animals was equal or greater than 2 standard deviations) from the 5th week of the 
Figure 2.  Effects of DIO and weight control interventions on aerobic capacity and glucose metabolism. (A) 
maximal oxygen consumption, maximum speed, and distance run during an incremental test were measured 
as markers of long term effects after 21 weeks of the experimental period, (B,C) glycemic profile and area under 
the curve after an oral glucose overload measured at 12, 15 or 21 weeks of the experimental period. Results are 
means of eight rats ± SEM depicted by vertical bars. *P < 0.05 in t-test (12 weeks); A,B,C means with different 
letters are significantly different (ANOVA treatment, P < 0.05; 15 and 21 weeks). AUC area under the curve 
(arbitrary units), SD normocaloric standard diet group, HFD HFD-treated group. Weight-loss interventions 
(WL) on weeks 13–15: WLs obese rats treated with caloric restriction and no exercise, WLe obese rats treated 
with caloric restriction in combination with physical exercise, WLsAM obese rats treated with caloric restriction 
in combination with AM251 administration and no exercise, WLeAM obese rats treated with caloric restriction 
in combination with physical exercise and AM251 administration. Weight-maintenance interventions (WM) 
on weeks 16–21: WMs rats treated with diet SD and no exercise, WMe rats treated with diet SD in combination 
with physical exercise, WMsAM rats treated with diet SD in combination with AM251 administration and no 
exercise, WMeAM rats treated with diet SD in combination with physical exercise and AM251 administration.
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DIO period by consuming an obesogenic diet compared to the normocaloric groups. Other models of DIO have 
been  described18,19. However, it should be highlighted that this dietary combination led to rapid weight gain in 
the experimental animals. Once obesity was established, the HFD diet continued to be administered along all 
the stages of the experimental period to clearly show the related alterations. Afterward, during the 12–15-week 
intervention period, different weight-loss strategies were implemented that resulted in subsequent body weight 
loss. Such decrease can be a consequence of several interacting factors like the high protein content of the diet 
due to its thermogenic action and its high levels of satiating soluble dietary fiber, the potential anorexigenic action 
of physical exercise, the inhibitory action on food intake of AM251 at the hypothalamus and leptin sensitivity 
which is usually inhibited by the consumption of a high-fat  diet20–23. In this context, administration of AM251 
has been shown to display dose-dependent decreases in food intake and weight gain, specially at doses of 2–5 mg/
kg24. In addition, the inhibitory action of AM251 can be potentiated by co-administration of leptin. Recently, 
a crosstalk between CB1 and GLP1 receptors has been described that provides new therapies for  obesity25. The 
coadministration of a peripheral CB1 receptor inhibitor with long-acting GLP1R agonists achieves greater reduc-
tion in body weight and fat mass than monotherapies by promoting negative energy balance.
During 15–21 weeks, weight-maintenance strategies were combined revealing that the combination of the 
three interventions assayed: a certain degree of caloric restriction, physical exercise, and administration of CB1 
receptor blocker was the most efficient to successfully maintain body weight and avoid the rebound effect com-
mon to other weight-loss treatments. In fact, during this last stage of the experimental period, the mixed training 
protocol and, especially, AM251 administration, contributed to maintain body weight via down-regulation of 
hypothalamic transcripts coding for Npy. Administration of AM251 has been reported to produce a significant 
decrease in the number of neurons expressing orexin A in the  hypothalamus26, whereas Orexin-A represses 
satiety-inducing POMC neurons and contributes to obesity via stimulation of endocannabinoid  signaling27. On 
Table 1.  Effects of DIO and weight control interventions on parameters of heart functionality. SD standard rat 
chow diet, HFD hypercaloric diet for dietary induction of obesity, WLs high protein weight-loss intervention 
diet with a sedentary lifestyle (weeks 12–15), WLe high protein weight-loss intervention diet with training 
protocol, WLsAM high protein weight-loss intervention diet with a sedentary lifestyle and pharmacological 
treatment with AM251, WLeAM high protein weight-loss intervention diet with training protocol and 
pharmacological treatment with AM251. WMs high protein weight-loss intervention diet with a sedentary 
lifestyle (weeks 12–15) followed by weight-maintenance stage (weeks 15–21) with SD dietary treatment 
and sedentary lifestyle, WMe high protein weight-loss intervention diet with training protocol followed by 
weight-maintenance stage with SD dietary treatment and training protocol, WMsAM high protein weight-loss 
intervention diet with a sedentary lifestyle and pharmacological treatment with AM251followed by weight-
maintenance stage with SD dietary treatment, sedentary lifestyle, and pharmacological treatment with AM251, 
WMeAM high protein weight-loss intervention diet with training protocol and pharmacological treatment 
with AM251 followed by weight-maintenance stage with SD dietary treatment, training protocol, and 
pharmacological treatment with AM251, Bpm bits per minute, QTc corrected QT interval. Results are means 
of 8 rats. SEM standard error of the mean. *P < 0.05 in t-test (12 weeks); a, b, c, means within the same column 




























SD 516.9 1.53 293.7 0.019 0.105 0.027 0.019 1.35 0.023 0.184 0.098
HFD 648.7*** 1.65 290.0 0.020 0.134* 0.025 0.020 1.69* 0.027 0.208* 0.106
SEM 19.7 0.045 7.3 0.002 0.010 0.002 0.003 0.075 0.001 0.035 0.056
15 weeks
SD 503.3b 1.41a 263.5a 0.029b 0.112a 0.059b 0.021a 1.15a 0.031a 0.220b 0.103a
HFD 704.1a 1.96b 242.4a 0.022b 0.066a 0.055b 0.021a 1.76b 0.040c 0.308b 0.128b
WLs 566.7c 1.54a 265.3a 0.024ab 0.117a 0.064b 0.021a 0.911a 0.042ab 0.143a 0.121ab
WLe 552.5bc 1.50a 260.9a 0.020b 0.130a 0.030a 0.021a 1.15a 0.041bc 0.192a 0.125b
WLsAM 544.2bc 1.55a 268.0a 0.025ab 0.119a 0.065b 0.020a 0.885a 0.064d 0.188a 0.171c
WLeAM 511.5bc 1.45a 254.4a 0.019b 0.106a 0.059b 0.020a 1.12a 0.041bc 0.161a 0.123b
SEM 21.2 0.09 7.8 0.002 0.041 0.003 0.001 0.105 0.002 0.015 0.006
21 weeks
SD 631.7a 1.69a 267.9a 0.021ab 0.089a 0.061ab 0.023ab 1.64b 0.042a 0.176a 0.134ab
HFD 803.8b 2.02b 274.5a 0.023b 0.129b 0.063ab 0.021a 1.97c 0.049a 0.291b 0.151b
WMs 634.2a 1.73a 263.7a 0.020ab 0.103ab 0.061ab 0.021a 1.09a 0.039a 0.203a 0.124a
WMe 574.4a 1.64a 255.9a 0.020ab 0.127a 0.067b 0.027b 1.14a 0.039a 0.206a 0.135ab
WMsAM 546.4a 1.72a 257.1a 0.022b 0.076a 0.057a 0.022ab 1.32a 0.045a 0.186a 0.134ab
WMeAM 590.9a 1.64a 273.9a 0.017c 0.095b 0.054a 0.021a 1.28a 0.049a 0.211a 0.152b
SEM 41.8 0.093 6.5 0.001 0.010 0.002 0.002 0.102 0.004 0.011 0.008
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the other hand, Di Marzo et al.28 reported that defective leptin signalling is associated with elevated hypothalamic 
levels of endocannabinoids in obese db/db and ob/ob mice and Zucker rats, whereas acute leptin treatment of 
normal rats and ob/ob mice reduces the endocannabinoids anandamide and 2-arachidonoyl glycerol in the 
hypothalamus.
DIO after consumption of HFD during 12 weeks resulted in the instauration of insulin resistance, as it is 
shown by the higher AUC after an oral glucose overload compared to SD groups Nevertheless, this pathological 
situation was reversed by weight loss interventions and AUC returned to values similar to those of SD animals. 
Other strategies including legume-derived functional ingredients and/or physical  exercise29 have also confirmed 
this beneficial action. Lost weight maintenance further improved the glycemic profile of the animals after the 
combined action of physical exercise and AM251 administration, enhancing metabolic activities that promote 
insulin sensitivity.
The CB1 receptor is highly expressed in central and peripheral nervous system, as well as various peripheral 
 tissues30,31. Evidence suggests that endocannabinoids are directly involved in the control of food intake and 
energy utilization by targeting these central and peripheral sites, including skeletal muscle, liver, and adipose 
 tissue32. The effects of AM251 on glucose metabolism can be explained in a similar way to other CB1 receptor 
inverse  agonists33 via metabolic “peripheral” action in adipose tissue in addition to its known “central” effect 
on food intake, thus providing an effective strategy for improving insulin sensitivity. The observed beneficial 
action of AM251 is also in agreement with the results of Esposito et al.34, who concluded that modulation of CB1 
receptor regulated uptake at the level of the PI3K signaling system in skeletal muscle cells. Therefore, interfering 
with CB1 signaling could ameliorate glucoregulatory functions in peripheral tissues. In a similar way, Crespillo 
et al.35 suggested that blockade of CB1 receptor could play an important role in the restoration of compromised 
metabolic status caused by high fat intake and improve cardiometabolic risk factors. Furthermore, in a recent 
Table 2.  Effects of DIO and weight control interventions on plasma parameters of heart and kidney 
functionality. SD standard rat chow diet, HFD hypercaloric diet for dietary induction of obesity, WLs high 
protein weight-loss intervention diet with a sedentary lifestyle (weeks 12–15), WLe high protein weight-loss 
intervention diet with training protocol, WLsAM high protein weight-loss intervention diet with a sedentary 
lifestyle and pharmacological treatment with AM251, WLeAM high protein weight-loss intervention diet with 
training protocol and pharmacological treatment with AM251. WMs high protein weight-loss intervention diet 
with a sedentary lifestyle (weeks 12–15) followed by weight-maintenance stage (weeks 15–21) with SD dietary 
treatment and sedentary lifestyle, WMe high protein weight-loss intervention diet with training protocol 
followed by weight-maintenance stage with SD dietary treatment and training protocol, WMsAM high protein 
weight-loss intervention diet with a sedentary lifestyle and pharmacological treatment with AM251 followed 
by weight-maintenance stage with SD dietary treatment, sedentary lifestyle, and pharmacological treatment 
with AM251, WMeAM high protein weight-loss intervention diet with training protocol and pharmacological 
treatment with AM251 followed by weight-maintenance stage with SD dietary treatment, training protocol, 
and pharmacological treatment with AM251. CK-MB creatine kinase MB. Results are means of 8 rats. SEM, 
standard error of the mean. *P < 0.05, ***P < 0.001 in t-test (12 weeks); a, b, c, means within the same column 
with different letters are significantly different (ANOVA treatment, P < 0.05; 15 and 21 weeks).
CK-MB (U/dL) ACE (U/dL)
Total Proteins 










SD 395.6 69.1 5.87 2.66 28.0 0.95 0.57 6.08 6.41
HFD 292.4 81.8 6.17* 2.92 32.7* 0.69 0.11 5.95 9.80***
SEM 0.16 0.67 0.14 0.15 0.16 0.16 0.08 0.41 0.67
15 weeks
SD 358.9a 73.4a 6.22c 3.33b 28.2a 0.94ab 0.71bc 6.13b 6.33a
HFD 987.0b 73.6a 6.51c 3.08ab 31.0a 0.90ab 0.15a 5.40ab 10.1b
WLs 335.6a 57.5b 5.57a 2.88ab 28.0a 0.72a 0.49abc 4.93a 6.59a
WLe 362.1a 77.3a 5.85ab 2.86ab 29.7a 0.92ab 0.81c 5.45ab 6.73a
WLsAM 213.6a 72.3a 5.34a 2.61a 34.0a 1.02ab 0.40ab 5.41ab 10.8b
WLeAM 196.1a 79.8a 5.42a 2.73ab 26.2a 1.19b 0.40ab 6.16b 11.0b
SEM 154.0 9.42 0.18 0.21 3.10 0.15 0.13 0.30 0.86
21 weeks
SD 166.7a 65.0a 6.39a 2.92ab 32.3b 0.78a 0.054a 6.28a 8.68a
HFD 571.7b 70.8b 6.07a 2.94ab 24.3ab 1.07a 0.046a 5.93a 9.51ab
WMs 206.4a 85.7bc 6.24a 3.09ab 24.0a 1.29ab 0.47a 5.59a 7.86a
WMe 207.6a 96.7d 6.09a 3.37b 26.6ab 0.86a 0.55a 5.99a 7.79a
WMsAM 283.0a 72.5b 6.00a 2.60a 25.6ab 1.29ab 0.54a 5.85a 11.1b
WMeAM 254.0a 75.4b 5.74a 3.09ab 40.6c 1.24ab 0.55a 5.63a 10.1ab
SEM 307.4 11.8 0.23 0.22 2.70 0.24 0.67 0.57 0.99
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study, Eid et al.36 have tested the effects of two neutral CB1 receptor antagonists (central and peripheral) with 
improved safety profiles on a preclinical model of insulin resistance. Both compounds alleviated insulin resistance 
peripherally, and exerted similar effects on rats with metabolic syndrome. They also displayed anti-dyslipidemic, 
anti-hyperuricemic and anti-inflammatory effects.
Consumption of a diet rich in saturated fats has been associated with changes in heart weight running in 
parallel to the development of obesity and insulin resistance and may cause ventricular modifications, increasing 
left ventricle mass that will, in turn, lead to diastolic and systolic alterations and modified left ventricle ejec-
tion  ratio37. Those changes are reflected in electrocardiographic modifications like the increased amplitude of 
QRS complex or QTc interval related to cardiac pathology and ventricular  arrhythmia38. Here, HFD-induced 
alterations in cardiac functionality appeared to be mostly related to the degree of cardiac hypertrophy and took 
place mainly at the ventricular level, resulting in the higher amplitude of QRS complex and T-wave as well as 
lengthening of the corrected QT interval. Pathological alteration of these parameters indicates disturbances in 
the electrical activity of the heart and, consequently, on the efficiency of pumping blood. Here, such changes 
began to show a trend at 12 weeks and were significant at 15 weeks. We have not observed any changes in ECG 
parameters related to atrial depolarization and conduction (P wavelength, P wave amplitude, or PR interval), 
reinforcing the idea that obesity affected mainly ventricular function. Modifications in ECG (QRS amplitude 
and T wave amplitude) were corrected after the weight loss interventions, although no additional effect to that 
of caloric restriction was achieved by exercise, CB1 receptor blockade, or the combination of both interven-
tions. Furthermore, no significant effect of exercise was found on QTc interval in a similar way to what has been 
reported in the obese Zucker rat  model39. The improvement in parameters of cardiovascular health achieved by 
Figure 3.  Effects of DIO and weight control interventions on vascular damage measured in the aorta and 
plasma. (A) gene expression of transcripts coding for vascular adhesion molecules and inflammation markers 
at the end of the 21-week experimental period, (B) plasma atherogenic index at the end of the different 
experimental stages. Results are means of eight rats ± SEM depicted by vertical bars. *P < 0.05 in t-test 
(12 weeks); A,B,C means with different letters are significantly different (ANOVA treatment, P < 0.05; 15 and 
21 weeks). Vcam vascular cell adhesion molecule 1, Vegfa Vascular endothelial growth factor A, Sele Selectin 
E, Nos2 Nitric oxide synthase 2, Ptgs2 Prostaglandin-endoperoxide synthase 2. Atherogenic index, (total-
cholesterol (mg/dL)/HDL-cholesterol (mg/dL). SD normocaloric standard diet group, HFD HFD-treated group. 
Weight loss interventions (WL) on weeks 13–15: WLs obese rats treated with caloric restriction and no exercise, 
WLe obese rats treated with caloric restriction in combination with physical exercise, WLsAM obese rats treated 
with caloric restriction in combination with AM251 administration and no exercise, WLeAM obese rats treated 
with caloric restriction in combination with physical exercise and AM251 administration. Weight-maintenance 
interventions (WM) on weeks 16–21: WMs rats treated with diet SD and no exercise, WMe rats treated with 
diet SD in combination with physical exercise, WMsAM rats treated with diet SD in combination with AM251 
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the weight-loss interventions and weight-maintenance was closely associated with significantly higher aerobic 
capacity and markers of physical fitness like maximum speed and total distance run during an incremental test. 
AM251 showed a very strong enhancing action on the later parameters in agreement with Zhou and  Shearman40 
who described a similar action of AM251 administration and physical activity on body weight loss and aerobic 
capacity. In contrast, Zhou and  Kumar41 stated that inhibition of CB1 receptors could have a negative influence 
on the practice of physical exercise. The benefits of AM251 can be attributed to the role played by CB1 receptors 
on skeletal muscle metabolism. Their blockade using the inverse agonist SR141716 has been described to induce 
a greater entrance of glucose from the bloodstream to muscle cells and potentially greater storage of energy 
during the practice of physical exercise, which, in turn, is consistent with the improvement in glucose AUC 42.
An important factor to be considered related to cardiac function is vascular functionality. In this regard, 
obesity, MetS, and lack of physical activity may cause endothelial dysfunction and early vascular  ageing43,44 by 
over-expression of vascular adhesion molecules associated with atherogenesis manifested before necrosis and 
coronary lesions. In our study, the increased aerobic capacity was associated with improved vascular health 
assessed by the aorta expression of different transcripts related to endothelial adhesion molecules (Sele and Vcam) 
and inflammation parameters (Nos2, Ptg2, Vegfa) at the end of the 21-week experimental period. Normalization 
of caloric intake as well as the mixed training protocol significantly down-regulated their expression, reaching 
values even lower than those of the SD group, and reduced the plasma atherogenic index, a widely used marker 
of dyslipidemia, obesity, and cardiovascular  disease45,46. Altogether, these results show a strong positive response 
to our weight loss and maintenance interventions at a cardiovascular level.
Obesity also represents a key risk factor for kidney disease. The consumption of HFD in our study caused a 
marked increase in their renal clearance rate, a measure of glomerular filtration, associated with albuminuria, 
a well-known marker of renal damage, both being reversed by the weight-loss and maintenance interventions 
of caloric restriction and physical exercise to values similar to SD group. Pharmacological treatment with spe-
cific CB1 receptor antagonist has been described to improve renal structure and functionality in experimental 
Table 3.  Effects of DIO and weight control interventions on urinary parameters of kidney functionality. SD 
standard rat chow diet, HFD hypercaloric diet for dietary induction of obesity, WLs high protein weight-
loss intervention diet with a sedentary lifestyle (weeks 12–15), WLe high protein weight-loss intervention 
diet with training protocol, WLsAM high protein weight-loss intervention diet with a sedentary lifestyle and 
pharmacological treatment with AM251, WLeAM high protein weight-loss intervention diet with training 
protocol and pharmacological treatment with AM251. WMs high protein weight-loss intervention diet with 
a sedentary lifestyle (weeks 12–15) followed by weight-maintenance stage (weeks 15–21) with SD dietary 
treatment and sedentary lifestyle, WMe high protein weight-loss intervention diet with training protocol 
followed by weight-maintenance stage with SD dietary treatment and training protocol, WMsAM high protein 
weight-loss intervention diet with a sedentary lifestyle and pharmacological treatment with AM251 followed 
by weight-maintenance stage with SD dietary treatment, sedentary lifestyle, and pharmacological treatment 
with AM251, WMeAM high protein weight-loss intervention diet with training protocol and pharmacological 
treatment with AM251 followed by weight-maintenance stage with SD dietary treatment, training protocol, 
and pharmacological treatment with AM251. Results are means of 8 rats. SEM, standard error of the mean. 
*P < 0.05, ***P < 0.001 in t-test (12 weeks); a, b, c, means within the same column with different letters are 












SD 6.25 7.86 2.22 12.08 0.081 89.7 1.53
HFD 4.33 6.10 88.9*** 3.15*** 0.062 94.2 3.76*
SEM 0.78 0.160 0.048 0.232 0.014 3.69 0.53
15 weeks
SD 5.99a 8.33c 2.31a 16.8b 0.077bc 79.50a 1.33ab
HFD 4.15a 6.73abc 88.8c 2.51a 0.112c 103.3b 2.55bc
WLs 5.37a 7.58bc 63.2bc 1.56a 0.061abc 88.4ab 1.41ab
WLe 5.26a 7.35bc 45.7b 2.43a 0.042ab 92.4ab 0.932a
WLsAM 13.2b 6.38ab 8.32a 8.95ab 0.012a 89.1ab 4.49d
WLeAM 12.1b 5.21a 3.60a 16.2b 0.034ab 77.6a 3.84 cd
SEM 1.11 0.838 10.32 2.711 0.017 7.07 0.47
21 weeks
SD 7.06b 6.79ab 81.2c 1.73a 0.042a 95.1a 3.90a
HFD 4.20a 6.45a 95.9c 4.89ab 0.168b 101.5a 3.60a
WMs 8.07b 7.98b 2.46a 13.5c 0.043a 88.1a 1.77a
WMe 7.83b 8.26b 2.48a 7.09abc 0.071ab 94.9a 1.94a
WMsAM 14.9c 8.20b 4.32a 10.9bc 0.057a 91.7a 3.65a
WMeAM 13.2c 6.42a 64.3b 9.54abc 0.062a 93.7a 4.10a
SEM 1.34 0.550 5.41 2.78 0.032 6.58 0.841
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models of chronic kidney  disease47. Moreover, a recent study by Udi et al.48 describes the administration of a 
novel peripherally restricted, orally bioavailable dual CB1 receptor/iNOS antagonist on a preclinical model of 
obesity-induced chronic kidney disease. The hybrid inhibitor ameliorated obesity-induced kidney morphological 
and functional changes via decreasing kidney inflammation, fibrosis, oxidative stress, and renal injury. Interest-
ingly, some of these features were independent of the improved metabolic profile induced by the inhibition of 
CB1 receptors. Here, AM251 administration contributed strongly to the weight loss strategy, helped to reverse 
the obesity-induced alterations in glucose metabolism and caused a significant increase in glomerular filtration 
rate and diuresis. However, in a different way to what was observed in animals fed the HFD, it did not correlate 
with the presence of albuminuria. In this regard, Jenkin et al.47 reported that chronic administration of AM251 
for 6 weeks with a daily dose of 3 mg/kg significantly reduced weight gain, systolic blood pressure, plasma 
leptin, albuminuria, plasma creatinine, and tubular cross-section diameter in a DIO model of Sprague Dawley 
rats, whereas Barutta et al.49 have reported that blockade of CB1 receptors ameliorates albuminuria in a diabetic 
nephropathy mice experimental model. Under our experimental conditions, the decreased albuminuria could 
also be due to a dilution effect associated with the higher diuresis in AM251-administered rats.
The increase of glomerular filtration rate resulting from AM251 administration is in agreement to what has 
been reported by Koura et al.50. Furthermore, Sampaio et al.51 have described the inhibitory action of the former 
compound in Na/k-ATPase activity of tubular cells. This would in turn decrease Na reabsorbtion and increase 
natriuresis, increasing urinary volume as observed in AM251-administered rats of the present study. On the other 
hand, obese rats of our experiment showed clear signs related to Parathormone activation at 12 or 15 weeks of 
Table 4.  Effects of DIO and weight control interventions on kidney antioxidant activities and lipid 
peroxidation. SD standard rat chow diet, HFD hypercaloric diet for dietary induction of obesity, WLs high 
protein weight-loss intervention diet with a sedentary lifestyle (weeks 12–15), WLe high protein weight-loss 
intervention diet with training protocol, WLsAM high protein weight-loss intervention diet with a sedentary 
lifestyle and pharmacological treatment with AM251, WLeAM high protein weight-loss intervention diet with 
training protocol and pharmacological treatment with AM251. WMs high protein weight-loss intervention diet 
with a sedentary lifestyle (weeks 12–15) followed by weight-maintenance stage (weeks 15–21) with SD dietary 
treatment and sedentary lifestyle, WMe high protein weight-loss intervention diet with training protocol 
followed by weight-maintenance stage with SD dietary treatment and training protocol, WMsAM high protein 
weight-loss intervention diet with a sedentary lifestyle and pharmacological treatment with AM251 followed 
by weight-maintenance stage with SD dietary treatment, sedentary lifestyle, and pharmacological treatment 
with AM251, WMeAM high protein weight-loss intervention diet with training protocol and pharmacological 
treatment with AM251 followed by weight-maintenance stage with SD dietary treatment, training protocol, 
and pharmacological treatment with AM251. SOD superoxide dismutase (Units/mg protein), CAT catalase 
(Units/mg protein), GPX glutathione peroxidase (nmol NADPH/min/mg protein), TBARS thiobarbituric acid 
reactive substances (nmol MDA/mg protein). Results are means of 8 rats. SEM standard error of the mean. 
**P < 0.01 in t-test (12 weeks); a, b, c, d, means within the same column with different letters are significantly 
different (ANOVA treatment, P < 0.05; 15 and 21 weeks).
Mn-SOD (UAA/mg/protein) Cu/Zn-SOD (UAA/mg/protein) CAT (U/mg/protein)
GPX (nmol NADPH/min/mg 
protein) TBARs (nmol MDA/mg protein)
12 weeks
SD 72.9 583.4 18.1 22.7 1.63
HFD 89.8** 581.3 20.9 26.4 1.24**
SEM 4.75 35.3 4.21 4.23 0.42
15 weeks
SD 35.1a 547.1b 13.9a 22.1a 0.71a
HFD 50.6b 785.1c 15.7ab 23.9a 1.33bc
WLs 56.6bc 569.4b 18.7bc 27.1ab 1.66c
Wle 61.2bcd 465.2ab 16.4abc 21.7a 1.47bc
WLsAM 65.7 cd 427.1a 19.8c 31.7b 1.42bc
WLeAM 71.1d 531.6ab 16.3abc 33.7b 0.99ab
SEM 4.20 37.1 1.28 2.32 0.07
21 weeks
SD 55.5a 449.5ab 26.1c 24.1a 0.902a
HFD 85.6 cd 353.1a 19.6abc 36.7c 1.15a
WMs 69.1abc 433.5ab 24.7c 31.5bc 0.984a
WMe 98.4d 374.4ab 20.7bc 30.1b 1.39a
WMsAM 81.5bcd 419.3ab 12.9a 24.1a 1.36a
WMeAM 63.5ab 374.4ab 14.7ab 18.9a 0.913a
SEM 6.34 33.1 2.42 1.95 0.17
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experimental period, characterized by increased phosphaturia and decreased calciuria. AM251 administration 
reversed such effects independently of weight loss after 3 weeks of AM251 treatment.
Alterations in renal antioxidant status induced by obesity are known to contribute to renal  damage52. DIO 
resulted in clear signs of kidney oxidative stress characterized by altered Mn and Cu/Zn-SOD and, to a lower 
extent, GPX activities, whereas the normalizing effects of weight control interventions were only relevant in Cu/
Zn-SOD status. Blockade of the CB1 receptor has been shown to protect against tubular damage attenuating 
renal oxidative stress and  inflammation53. Under our experimental conditions, administration of AM251 was 
effective at normalizing the status of Mn-SOD and GPX activity at week 21.
In conclusion, weight-loss and maintenance intervention strategies tested were efficient at reversing the 
obesity-related alterations in body weight, aerobic capacity, glucose metabolism, cardiovascular and renal func-
tion. The beneficial action was very consistent for caloric restriction and physical exercise, whereas AM251 
administration complemented their effects on parameters like body weight and exhibited significant benefits on 
aerobic capacity. The implementation of weight control strategies in overweight or obese subjects that can avoid 
the post-treatment rebound effects are very effective measures to revert the metabolic, cardiovascular, and renal 
alterations developed in parallel to caloric imbalance, sedentarism, and obesity.
Material and methods
Animals and experimental design. The selection of the right in vivo experimental model is a crucial 
point in obesity studies. The Sprague Dawley rat is an adequate animal model of diet-induced obesity (DIO) as 
it develops obesity, dyslipidemia, insulin resistance, hypertriglyceridemia, and altered cardiovascular and renal 
functionality after the intake of a high-fat diet (HFD) for a period of 8–12  weeks54. The experiment used 112 
male Sprague Dawley rats with an average body weight of 184 ± 10 g (6-weeks old, Charles Rives, Barcelona, 
Spain) that were allocated into fourteen different experimental groups (n = 8/group). The animals were housed 
in a well-ventilated, thermostatically controlled room (21 ± 2 °C) (Unidad de Experimentación Animal, CIC, 
Universidad de Granada). A reversed 12:12 light/dark cycle was implemented so that AM251 administration 
and the training protocol would be performed in darkness. Throughout the trial, animals had free access to type 
2 water (resistivity 15 MΩ−cm) and consumed the diet ad libitum, except the intervention groups in the weight-
maintenance stage of the experiment that were adapted to slightly lower food intake.
The experiments lasted for 21 weeks and included three different stages: (i) obesity induction and related 
metabolic alterations 0–12th week, (ii) weight-loss intervention 12th–15th week and (iii) weight maintenance 
intervention 15th–21st week) (Fig. 1A).
Throughout the experimental period, a standard normocaloric group was used as a control diet, SD (Teklad 
Global Diet 2014; 2.4 kcal/g) for the different stages. Obesity was induced using a hypercaloric obesogenic diet, 
HFD (including 60% of kcal as fat, Research diets D12492; 5.2 kcal/g), for 21 weeks. The weight-loss intervention 
stage (WL) included a caloric restriction strategy based on a reduction in the amount of food consumed and 
using a high protein and soluble fiber diet (2.5 kcal/g, Table 5) with/without physical exercise intervention, for 
3 weeks and/or administration of AM251 inhibitor. Finally, the experiments continued with a weight-mainte-
nance intervention (WM) that was achieved by the inclusion of a standard normocaloric diet, for 6 weeks, pair 
fed to 23 g/days to achieve a 12–15% caloric reduction compared to the same period in control SD group as part 
of the strategy to maintain the lost weight during maintenance stage avoiding the rebound  effect55 with/without 
physical exercise intervention, and/or administration of AM251 inhibitor.
Table 5.  Nutrient composition of the experimental diets. SD standard rat chow, HFD hypercaloric diet for 
dietary induction of obesity, WL high protein intervention diet for weight loss. Formulation of WL diet per 
100 g: pea protein isolate 21%, whey protein isolate 18%, cysteine 0.2%, olive oil 4%, Cellulose 11%, Plantago 
ovata fiber 11%, AIN93M mineral premix 3.5%, AIN93M vitamin premix 1%, coline bitartrate 0.25%, dextrins 
15%, wheat starch 15%.
SD HFD WL
Protein (%) 13.5 22.2 26.7
Ash (%) 4.53 4.11 4.2
Fiber (%) 22.3 5.0 23.1
Carbohydrate (by difference) (%) 55.3 37.5 41.8
Energy (Kcal/g) 2.4 5.2 2.5
Fat (%) 4.41 31.2 4.23
Fatty acid profile (%)
Miristic (C14:0) – 0.25 –
Palmitic (C16:0) 10.36 21.33 7.20
Stearic (C18:0) 0.46 7.10 1.30
Palmitoleic (C16:1n9) – 0.36 –
Oleic (C18:1n9) 12.84 41.62 78.16
Octadecenoic (C18:1n7) – 0.36 –
Linoleic (C18:2n6) 74.35 27.86 12.42
Linolenic (C18:3n3) 1.99 1.13 0.92
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The administration of AM251 was carried out by intraperitoneal injection thrice a week (Monday, Wednes-
day, Friday at 9:00 a.m.) at a dose of 3 mg/kg body  weight56 during the 3-week weight-loss intervention (WL, 
12–15 weeks) and once a week during the maintenance period (WM, 16–21 weeks).
The weight-loss intervention and bodyweight maintenance periods have been designed based on the informa-
tion provided by  Sengupta57 who reported that laboratory rats live about 2–3.5 years (average 3 years), while the 
worldwide life expectancy of humans is 80 years. Thus, one human year almost equals two rat weeks (13.8 rat 
days) when correlating their entire life span. Under our experimental conditions, 3 weeks equal to 1.5 years of 
human life, which is a long enough period to achieve an efficient weight loss. The maintenance period of 6 weeks 
equals 3 years which is enough to demonstrate the success of our combined strategy against bodyweight-regain.
The composition of different experimental diets is shown in Table 5.
The diet was provided for all four animals in each cage but the bodyweight control was registered individu-
ally. Caloric intake was recorded daily whereas body weight was measured once a week. During the last week of 
each experimental stage, a 12 h fasting urine sample collection was performed for each animal located during 
that time in individual metabolic cages designed to achieve a separate collection of feces and urine. Volume, pH, 
and other biochemical parameters were then measured in urine. Moreover, a glucose overload tolerance test was 
performed 48 h after the last training session. The animals were allowed to recover for 48 h before fasting for a 
further 8 h, followed by anesthesia with ketamine (75 mg/kg body weight) and xylazine (10 mg/kg body weight) 
and electrocardiogram recording before sacrifice by exanguination. Blood was collected by puncture of the 
abdominal aorta (with heparin as an anticoagulant). An aliquot of 0.25 mL was used to assess blood parameters 
(KX-21 Automated Hematology Analyzer, Sysmex Corporation), and the rest was centrifuged at 1458×g for 
15 min to separate plasma that was subsequently frozen in liquid nitrogen and stored at – 80 °C58. The kidney 
and heart were extracted, weighed, and immediately frozen in liquid nitrogen and stored at − 80 °C until they 
were processed for antioxidant activity assessment and RNA extraction. The whole hypothalamus and descend-
ing aorta were extracted, immersed in RNA preserving solution (RNAlater, Ambion), and stored frozen until 
RNA extraction. The femur was extracted and its length was measured with a caliper before freezing in liquid 
nitrogen and storage at − 80 °C. All experiments were undertaken according to Directional Guides Related to 
Animal Housing and  Care59 and all procedures were approved by the Animal Experimentation Ethics Committee 
of the University of Granada, Spain (Project Reference DEP2014-58296R).
Training protocol. Rats trained following a protocol based on interval aerobic training combined with 
strength exercise in the same  session60,61. The animals run on a specially designed treadmill (Panlab, LE 8710R) 
and all sessions were performed 5 days/week, during the dark cycle of the animals. A final incremental test 
following the protocol described by Wisløff et al.62 and Clemente et al.63 was performed 96 h before the end of 
the weight-maintenance stage to test the maximal aerobic capacity and physical performance achieved by the 
animals as a result of the interventions.
Intraperitoneal administration of AM251. The CB1 receptor inverse agonist, N-(Piperidin-1-yl)-5 
(4-iodophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM251) (Tocris Cookson, UK) 
was dissolved in the vehicle dimethyl sulfoxide:tween-80:0.9% NaCl (1:2:97) for intraperitoneal administration 
in rats at a dose of 3 mg/kg body  weight58.
Determination of body weight to femur length ratio. Bodyweight and femur length of the rats in 
all the control and experimental groups were measured at the end of every experimental stage (12, 15, and 
21 weeks). Bodyweight to femur length ratio was determined by dividing body weight (g) by the square of femur 
length (cm) as a representative measure of the animal’s nose-anus length.
Blood, plasma, and urine biochemical analysis. Fasting blood glucose and glucose tolerance tests 
were performed by oral glucose overload as previously  described64 using a dose of 6.9 µmol glucose per gram 
body weight. The area under the curve (AUC) was calculated following the trapezoidal  rule65. Plasma and uri-
nary biochemical parameters were analyzed using a Shenzhen Midray BS-200 Chemistry Analyzer (Bio-Med-
ical Electronics). Analytical kits (Spin-React, Spain) were used to measure the following parameters in plasma 
[total-cholesterol, HDL-cholesterol, uric acid, urea, creatinine, total protein, albumin, Ca, P, creatine kinase MB 
(CK-MB), and angiotensin-converting enzyme activity (ACE)], and urine [total protein, albumin, creatinine]. 
Plasma atherogenic Index (AI) was calculated with the formula: AI = (total cholesterol  −  HDL-cholesterol)/
HDL-cholesterol. Urinary pH was analyzed using a bench pH-meter. Renal creatinine clearance rate as an index 
of glomerular filtration rate was calculated using the standard formula C = U × V/P, where U is the concentration 
in urine (mg/dL), V is the urine flow rate (mL/min), and P is the plasma concentration (mg/dL).
Electrocardiogram recording. ECG was recorded as previously  described66 with surface electrodes for 
1 min using the LabChart 7 software (AD Instruments, USA) at the end of the experimental period. The aver-
age value for each rat was obtained from values of ten consecutive cardiac cycles measured at 10, 30, and 50 s. 
The following parameters were measured: P-wave length and amplitude, PQ interval, QRS complex length and 
amplitude, T-wave length and amplitude, and QT interval. Corrected QT interval (QTc) was calculated using 
Bazett’s Formula (QTc = QT interval/√(RR interval).
RNA extraction and quantitative RT‑PCR. Total RNA was isolated from the whole hypothalamus and 
the descending aorta by homogenization in 1 mL of Tri-Reagent (Sigma-Aldrich). The RNA was solubilized in 
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Rnase-free  H2O and treated with DNase (Applied Biosystems) to remove any DNA present in the sample. A 
total of 100–250 ng of RNA was reverse-transcribed according to standard protocols using a Lifepro Thermal 
Cycler (Bioer Serves Life, China). Quantitative RT-PCR was performed with 7900 HT Fast Real-Time PCR 
system (Applied Biosystems), using primer/probes for genes involved in food intake and energy metabolism 
in the hypothalamus [fos, Npy, Hcrt, Lepr, Cnr] or genes coding for adhesion proteins and enzymes involved in 
inflammatory pathways in the descending aorta [Vcam, Sele, Vegfa, Nos2, Ptgs2] (Applied Biosystems). The PCR 
master mix reaction included the first-strand cDNA template, primers/probes, and 2X TaqMan Fast Universal 
PCR Master Mix, No AmpErase UNG (Applied Biosystems). Relative quantification was performed using the 
comparative Ct (2 − ΔΔCt)  method67. ß-actin was used as internal control.
Kidney antioxidant activity and lipid peroxidation assays. A fresh kidney aliquot was homogenized 
(1:10 w/v) in 50  mM phosphate buffer (pH 7.8) containing 0.1% Triton X-100 and 1.34  mM of DETAPAC. 
Kidney homogenates were centrifuged at 13,000×g, 4 °C for 45 min, and the supernatant was used to determine 
the activity of antioxidant enzymes. Catalase activity was assayed according to Cohen et al.68, total cellular Glu-
tathione Peroxidase (GPX) activity by the coupled assay of NADPH  oxidation69 using cumene hydroperoxide as 
substrate, and total superoxide dismutase (SOD) activity following the methodology of Ukeda et al.70. Mn-SOD 
activity was determined by the same method after treating the samples with 4 mM KCN for 30 min. Cu/Zn-SOD 
activity resulted from the subtraction of Mn-SOD activity from the total SOD activity. Protein concentration 
was assayed by the method of  Bradford71. Lipid peroxidation was determined in kidney homogenates according 
to the methodology of Ohkawa et al.72. Thiobarbituric acid reactive substances (TBARS) were assayed spectro-
photometrically at 532 nm.
Statistical analyses. Significant differences in aerobic capacity, glycemic profile, plasma, and urinary 
biochemical parameters and indices, electrocardiographic parameters, gene expression data, and kidney anti-
oxidant enzyme activity data between SD and HFD groups were analyzed by t-test at the end of DIO stage 
(12 weeks). At the end of weight-loss (WL, 13–15 weeks) and weight-maintenance (WM, 16–21 weeks) stages, 
significant differences were analyzed by one-way ANOVA among all experimental groups in each stage. Tukey’s 
test was used to detect differences between treatment means. Statistical analysis was performed with Statistical 
Package for Social Sciences (IBM SPSS for Windows, version 22.0, Armonk, NY), and the level of significance 
was set at p < 0.05.
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